< %=imgalt%>
US Elections Calendar ~ Barak Obama ~ Iftikhar Muhammad Chaudhry ~ Other International News
Home / International News / Press Releases / September 04, 2008
American Oriental Bioengineering Announces Participation in September Investor Conferences

Top News

Chiranjeevi welcomes newcomers with clean record into politics

Tony Blair vows for a coordinated effort to tackle global meltdown

Pak Govt. hasnt provided funds for pleading Aafias case

Bruce Springsteen bags Billboards Top Tour award

American tax payers ready to let Big Three automakers go under

Dhoni refutes rift over team selection

Party advertised on Facebook ends in chaos after 60 gatecrash the event

Modern plagues share certain features with ancient ones

American Oriental Bioengineering Announces Participation in September Investor Conferences

NEW YORK, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced that the Company will present at the following conferences:

    1. Morgan Stanley Global Healthcare Unplugged Conference, held at the
       Grand Hyatt in New York on September 9, 2008;
    2. Merrill Lynch Global Pharmaceutical Conference, held at the Merrill
       Lynch Financial Centre in London on September 17, 2008;
    3. UBS Global Life Sciences Conference, held at the Grand Hyatt in New
       York on September 25, 2008.  To access the webcast of this event,
       please go to http://www.ibb.ubs.com/ .

Management will also hold one-on-one meetings at the conferences. For more details on the aforementioned conferences, please visit the respective conference organizers websites.

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

SOURCE American Oriental Bioengineering, Inc.

International News / Press Release source: PR Newswire
Copyright PR Newswire. All Rights Reserved.

International Business News / Press Releases

Mechel Consolidates Its Ferroalloy Assets
PR Newswire

Subaye.com Acquires 3,310 Corporate Video Members at China IE Fair (Canton Fair)
PR Newswire

Crowe Horwath LLP and Grobstein, Horwath & Company LLP Announce Transaction
PR Newswire

Technology to Rescue Publishers
PR Newswire

AgFeed Industries, Inc. Announces That the Company Has Never Utilized Melamine in its Products or Raw Material
PR Newswire

International Health News / Press Releases

Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of China's Ministry of Science and Technology
PR Newswire

Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
PR Newswire

China Yingxia International, Inc. to Promote Benefits of Its Soy Milk Products Over Scandal-Stricken Cow's Milk in China
PR Newswire

New Study Reveals Consumers Want Greater Say in Key Food Issues
PR Newswire

China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
PR Newswire

International Medical News / Press Releases

Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
PR Newswire

China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
PR Newswire

InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
PR Newswire

Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
PR Newswire

New Study Finds Growth Factor Boosts Productivity in Mammalian Cell Culture
PR Newswire